Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 3, 2009, Pages 503-512

  Pratley, Richard E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b University of Vermont Colchester Research Facility   (United States)

Author keywords

Alogliptin; Dipeptidyl peptidase 4; Glucagon like peptide 1; Incretin; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FLUCONAZOLE; GASTRIC INHIBITORY POLYPEPTIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; KETOCONAZOLE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; WARFARIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE; URACIL;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; AREA UNDER THE CURVE; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LONG TERM CARE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING; DOSE RESPONSE; DRUG COMBINATION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PIPERIDINES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; URACIL;

EID: 65649116135     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802694713     Document Type: Review

References (44)

1. International Diabetes Federation. Diabetes Atlas 2007. Available from: www.info.idf.org [Last accessed 18 October 2008 ]
2. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002, the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537
3. Diabetes Control and Complications Trial (DCCT) Research Group. N Engl J Med 1993;329:977-986
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
5. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972
6. Ford ES, Li C, Little RR, et al. Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008;31:102-104
7. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
8. Takeda submits new drug application for alogliptin (SYR-322) in the US. Takeda Pharm Co. Ltd. Press release, 3 January 2008
9. FDA approves once-daily Januvia, the first and only DPP-IV inhibitor available in the United States for type 2 diabetes. Merck & Co Inc. Press release, 17 October 2006
10. Galvus receives European approval as new treatment for type 2 diabetes with broad range of indications. Novartis. Press release, 28 September 2007
11. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2939 •• An excellent overview of the basis for incretin therapies. (Pubitemid 37205571)
12. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165 •• The pleotropic effects of GLP-1 and GIP are succinctly reviewed in this paper. (Pubitemid 43316521)
13. Amori RE, Lau J, Pittas AG, et al. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
14. Deacon CF. Therapeutic strategies based on glucagon-like peptide-1. Diabetes 2004;53:2181-2189 (Pubitemid 39145569)
15. Drucker DJ, Nauck MA. The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
16. Holst JJ, Vilsboll T. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2008: published online 8 August 2008, doi:10.1016/j.mce.2008.08.012
17. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-307 • Provides much of the rationale for targeting GLP-1 rather than GIP as a therapy for type 2 diabetes. (Pubitemid 23037285)
18. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678-687
19. Feng J, Zhang Z, Wallace MB, et al. Discovery of Alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-2300 • An interesting overview of a structure-based approach to drug development. (Pubitemid 46799241)
20. Lankas GR, Leiting B, Sinha Roy R, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-2994 (Pubitemid 41401097)
21. Lee B, Shi L, Kassel DB, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008;589:306-314
22. Takeuchi K, Moritoh Y, Asakawa T, et al. Effects of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, alone or in combination with pioglitazone in obese and non-obese type 2 diabetes model rats and mice. Diabetes 2006;55(6 Suppl 1):2010
23. Moritoh Y, Takeuchi K, Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharm 2008;588:325-332
24. Moritoh Y, Takeuchi K, Kataoka O, et al. Effect of combination treatment with alogliptin (SYR-322), a novel dipeptidyl peptidase-IV inhibitor, and pioglitazone on glycemic control in ob/ob mice. Diabetes 2007;56(Suppl 1):2151
25. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008;9:402-413 •• A thorough review of the preclinical and early clinical studies of Alogliptin.
26. Karim A, Bridson WE, Fleck P, et al. Disposition of the dipeptidyl peptidase-4 inhibitor [14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects. Am Assoc Pharm Scientists J 2007;9(Suppl 2)
27. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-527
28. Hirayama M, Matsuno K, Fujita T, et al. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Diabetes 2008;57(Suppl 1):521
29. Karim A, Fleck P, Hetman L, et al. Single-dose Pharmacokinetics of the dipeptidyl Peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008;57(Suppl 1):538
30. Karim A, Fleck P, Dorsey D, et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment. J Clin Pharmacol 2007;47:107
31. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512
32. Karim A, Harris S, Schuster J, et al. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state. J Clin Pharmacol 2007;47:106
33. Karim A, Fleck P, Harris S, et al. Effect of fluconazole, ketoconazole and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects. J Clin Pharmacol 2007;47:105
34. Covington P, Christopher R, Davenport M, et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. Diabetes 2007;56(Suppl 1):2136
35. Karim A, Fleck P, Joseph M, et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride. Diabetes 2007;56(Suppl 1):2117
36. Fleck P, Karim A, Harris S, et al. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects. Diabetes 2007;56(Suppl 1):2135
37. Fleck P, Christopher R, Covington P, et al. Efficacy and safety of alogliptin monotherapy in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):479
38. DeFronzo R, Fleck P, Wilson C, et al. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):446
39. Pratley R, Kipnes M, Fleck P, et al. Alogliptin added to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Diabetes 2008;57(Suppl 1):445
40. Nauck M, Ellis G, Fleck P, et al. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):477
41. Pratley R, Reusch J, Fleck P, et al. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):478
42. Rosenstock J, Rendell M, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Diabetes 2008;57(Suppl 1):444
43. Nathan DM. Finding new treatments for diabetes-how many, how fast ... how good? N Engl J Med 2007;356:437-440
44. Bloomgarten ZT, Dodis Z, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy. Diabetes Care 2006;29:2137-2139 • This meta-analysis demonstrates the importance of baseline A1C when evaluating the efficacy of diabetes therapeutics.